                         SEQUENCE LISTING

<110>  Affimed GmbH
 
<120>  Combination of a bispecific CD30xCD16  antibody with an immune 
       modulating moleculea PD-1 antagonist for therapy

<130>  A 3283PCT

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  483
<212>  PRT
<213>  artificial sequence

<220>
<223>  Fv tandem diabody

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ser Ala Tyr Tyr Tyr Asp Phe Ala Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser Gly Gly Ser Gly Gly Ser Gly Gly 
        115                 120                 125             


Ser Asp Ile Val Met Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val 
    130                 135                 140                 


Gly Asp Arg Val Thr Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr 
145                 150                 155                 160 


Asn Val Ala Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro Lys Val Leu 
                165                 170                 175     


Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr 
            180                 185                 190         


Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln 
        195                 200                 205             


Ser Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr His Thr Tyr Pro 
    210                 215                 220                 


Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Asn Gly Gly Ser Gly 
225                 230                 235                 240 


Gly Ser Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu 
                245                 250                 255     


Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr 
            260                 265                 270         


Thr Phe Thr Thr Tyr Thr Ile His Trp Val Arg Gln Arg Pro Gly His 
        275                 280                 285             


Asp Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Ser Asp 
    290                 295                 300                 


Tyr Asn Gln Asn Phe Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser 
305                 310                 315                 320 


Ser Asn Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser 
                325                 330                 335     


Ala Val Tyr Tyr Cys Ala Arg Arg Ala Asp Tyr Gly Asn Tyr Glu Tyr 
            340                 345                 350         


Thr Trp Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        355                 360                 365             


Gly Gly Ser Gly Gly Ser Gly Gly Ser Ser Tyr Val Leu Thr Gln Pro 
    370                 375                 380                 


Ser Ser Val Ser Val Ala Pro Gly Gln Thr Ala Thr Ile Ser Cys Gly 
385                 390                 395                 400 


Gly His Asn Ile Gly Ser Lys Asn Val His Trp Tyr Gln Gln Arg Pro 
                405                 410                 415     


Gly Gln Ser Pro Val Leu Val Ile Tyr Gln Asp Asn Lys Arg Pro Ser 
            420                 425                 430         


Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr 
        435                 440                 445             


Leu Thr Ile Ser Gly Thr Gln Ala Met Asp Glu Ala Asp Tyr Tyr Cys 
    450                 455                 460                 


Gln Val Trp Asp Asn Tyr Ser Val Leu Phe Gly Gly Gly Thr Lys Leu 
465                 470                 475                 480 


Thr Val Leu 
            


<210>  2
<211>  123
<212>  PRT
<213>  artificial sequence

<220>
<223>  FH of anti-CD30 domain

<400>  2

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 
            20                  25                  30          


Thr Ile His Trp Val Arg Gln Arg Pro Gly His Asp Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Ser Asp Tyr Asn Gln Asn Phe 
    50                  55                  60                  


Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr 
65                  70                  75                  80  


Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Arg Ala Asp Tyr Gly Asn Tyr Glu Tyr Thr Trp Phe Ala Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  3
<211>  107
<212>  PRT
<213>  artificial sequence

<220>
<223>  VL of anti-CD30 domain

<400>  3

Asp Ile Val Met Thr Gln Ser Pro Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Val Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Asn 
            20                  25                  30          


Val Ala Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro Lys Val Leu Ile 
        35                  40                  45              


Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser 
65                  70                  75                  80  


Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr His Thr Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Asn 
            100                 105         


<210>  4
<211>  120
<212>  PRT
<213>  artificial sequence

<220>
<223>  VH of anti-CD16A

<400>  4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 
1               5                   10                  15      


Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 
            20                  25                  30          


Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Ser Ala Tyr Tyr Tyr Asp Phe Ala Asp Tyr Trp Gly Gln 
            100                 105                 110         


Gly Thr Leu Val Thr Val Ser Ser 
        115                 120 


<210>  5
<211>  106
<212>  PRT
<213>  artificial sequence

<220>
<223>  VL of anti-CD16A domain

<400>  5

Ser Tyr Val Leu Thr Gln Pro Ser Ser Val Ser Val Ala Pro Gly Gln 
1               5                   10                  15      


Thr Ala Thr Ile Ser Cys Gly Gly His Asn Ile Gly Ser Lys Asn Val 
            20                  25                  30          


His Trp Tyr Gln Gln Arg Pro Gly Gln Ser Pro Val Leu Val Ile Tyr 
        35                  40                  45              


Gln Asp Asn Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  


Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 
65                  70                  75                  80  


Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Asn Tyr Ser Val Leu 
                85                  90                  95      


Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105     


